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Cardiac resynchronization therapy (CRT) is a relatively 
new therapeutic option for patients with systolic heart 
failure (HF) and electrocardiographic evidence of 
dyssynchrony. However, with current selection guidelines, 
still a proportion of patients do not respond to this 
interventional therapy. Several echocardiographic criteria 
have been proposed to address this issue, but research so 
far has failed to provide a single and simple measurement 
with adequate accuracy for CRT candidate selection. 
While investigation for this subject is still under way, new 
possible roles of echocardiography in CRT 
implementation arise, such as assistance in selecting the 
site of left ventricular (LV) pacing lead and optimizing 
CRT device programming during follow up visits.  
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Introduction 
 
Despite advances in medical therapy, prognosis of HF 
patients remains poor.1,2 It is estimated that at least 20% of 
patients with systolic HF have evidence of conduction 
delay in their surface electrocardiogram (ECG), expressed 
by QRS prolongation.2–4 For this subgroup of patients, 
which is reported to have higher mortality rates compared 
to those with normal QRS duration,3 CRT is an established 
therapeutic option. CRT aims to restore the electrical 
dyssynchrony and its benefit has been proven in wide 
range of randomized clinical trials (RCTs).5–18  
However, in the aforementioned RCTs, a significant 
proportion of patients, as much as 30%, did not respond to 
this interventional approach, despite fulfilling selection 
criteria. Taking into account the possible complications of 
biventricular (BiV) pacing, and the substantial cost, 
alternative selection tools have been sought. At the same 
time, it has been suggested that electrical dyssynchrony 
(QRS >120 ms)19 is not  sensitive enough to pinpoint the 
presence of mechanical dyssynchrony,20–22 which in turn 
might be more important than electrical dyssynchrony.23,24  
Mechanical dyssynchrony can be further divided into 
three main types. Atrioventricular dyssynchrony is the 
discordance between atrial and ventricular systole, which 
impacts ventricular filling and is important for CRT 
optimization.25 Interventricular dyssynchrony refers to the 
delay between the onset of left and right ventricular 
contraction.26–28 But even more important is the presence 
of intraventricular dyssynchrony, which reflects the delay 




Echocardiography, has been deemed a suitable tool to 
detect the presence of mechanical dyssynchrony. Various 
measurements have been described based in almost all 
echo modalities. 
Septal-to-posterior wall motion delay (SPWMD) is a 
simple index that measures the time from QRS onset to 
peak systolic movement of both the interventricular 
septum and the posterior wall, from the parasternal long 
axis view at mid ventricular level using m-mode.30 The 
cut-off value has been set at 130 ms, but the technique can 
been further enhanced with the addition of color-coded 
tissue Doppler imaging (TDI), with a cut-off value of 252 
ms.31,32  
Lateral wall post-systolic displacement (LWPSD) is 
also based on M-mode. It compares maximal systolic 
movement of lateral wall with the onset of transmitral 
flow, and there is evidence of dyssynchrony when systolic 
wall movement exceeds mitral valve opening.33 In any 
case, due to M-mode’s limitations, the American Society 
of Echocardiography recommends to use M-mode based 
techniques only as an addition to another echo modality for 
dyssynchrony estimation.31  
Left ventricular preejection interval (LPEI) is an index 
based on pulse-wave Doppler, and identifies dyssynchrony 
when >140 ms lapse between onset of QRS and aortic 
valve opening. In a more recent report, total isovolumic 
time – IVT (which is the sum of the time between aortic 
valve closure and mitral valve opening and vice versa) had 
at least equal predictive value with newer echo 
techniques.32 Interventricular delay, defined by a 
difference >40 ms between the onset of aortic and 
pulmonary artery flow, is also based on pulse wave 
Doppler.34   
TDI has been widely used for the detection of 
dyssynchrony. Pulse wave TDI can be used to measure the 
time between QRS and peak systole (time to Sm peak) or 
the onset of systole (time to Sm onset) in basal and mid LV 
segments. Opposing wall delay >65 ms has been estimated 
to predict CRT response with as much as 80% sensitivity 
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and 92% specificity.35 It is important to note that TDI is 
not suitable for application in the apical LV segments.36 Yu 
and al, after measuring the time to peak systolic velocity in 
all 12 basal and mid segments, define as “Dyssynchrony 
Index” (DI) the standard deviation of these 12 
measurements, which is reported to predict CRT response 
with high specificity and almost 100% sensitivity, in the 
studied population, when the cut-off is set at 32.6 ms.37,38 
Many investigators have published reports with numerous 
TDI indices, which differ in the timing of the 
measurements or the mathematical processing of the 
results, but their full presentation is beyond the scope of 
this review. However, it is important to note that TDI can 
be used to measure strain-rate and, subsequently, strain.  
Standard deviation of time-to-peak-strain (TPS-SD) in the 
6 basal and 6 mid LV segments, can detect dyssynchrony, 
with a cut-off of 60 ms, at least in patients with dilated 
cardiomyopathy.39  
Speckle tracking echo (STE) is a novel 
echocardiographic modality, which identifies and tracks 
the movement of echogenic speckles in LV wall across 
ensuing frames, order to measure primarily strain, and 
strain rate. Strain can be further divided in longitudinal, 
circumferential and radial, depending on the axis of LV 
wall deformation. Suffoletto and al measured time to peak 
systolic radial strain in the mid segments of LV wall, from 
parasternal short axis view. Difference > 130 ms between 
anteroseptal and posterior wall predicted CRT response 
with sensitivity of 89-91% and specificity of 75-83%.40 
There are also reports about measuring strain in another 
axis, but as far as dyssynchrony is concerned, most studies 
use the radial strain.41 The Speckle Tracking and 
Resynchronization (STAR) prospective multi-center study 
tested whether STE can predict response to CRT. Baseline 
dyssynchrony was evaluated by 4 speckle tracking strain 
methods; radial, circumferential, transverse, and 
longitudinal (>130 ms opposing wall delay for each). Once 
again, radial strain had the highest sensitivity at 86% and 
specificity of 67% for predicting LV ejection fraction 
(LVEF) response. Serious long-term unfavorable events 
occurred after CRT, and happened 3 times more frequently 
in those who lacked baseline radial or transverse 
dyssynchrony than in patients with dyssynchrony. On the 
other hand, circumferential and longitudinal strains 
predicted response when dyssynchrony was detected, but 
failed to identify dyssynchrony in one-third of patients 
who responded to CRT.42 Using STE again, this time to 
measure strain rate, Wang et al devised “LV 
discoordination index “(percent of stretch/shortening or 
thinning/thickening during ejection). A mid-ventricular 
radial discoordination index (RDI-M) >38% best predicted 
responders, especially in patients with ischemic 
cardiomyopathy.43 With the use of STE, measurement of 
LV twist (and torsion) is also feasible, and connected to 
CRT response.44–47  
Detection of inotropic contractile reserve, during stress 
echocardiography with low dose dobutamine, is a feasible 
method that could help identify possible CRT-responders 
with sensitivity of 76.9% and specificity of 85.7-86%, if 
an augmentation in LV ejection fraction of >5-7.5% is 
observed.48,49 Viability of the LV wall, targeted for BiV 
pacing, should also be sought. Increase in strain (measures 
by STE) of at least 6% during low dose dobutamine 
infusion, is in favor of CRT response.49  
Real time 3D echocardiography is the latest 
development in echo imaging, has the advantage of not 
being limited by geometric assumptions as 2D imaging,  
and could be used to screen for possible CRT responders. 
Kapetanakis et al after acquiring full volume LV loops 
from the apical window, divided this volume into 
pyramidal subvolumes based around a non-fixed central 
point, in order to gain an estimation of time-volume data 
corresponding to each of the 16 standard myocardial 
segments. They then calculated the time taken to reach 
minimum regional volume for each segment, and 
expressed it as a percentage of the cardiac cycle. The 
systolic dyssynchrony index (SDI) was defined as the 
standard deviation of these timings, and was later given a 
cut-off value of 5.6%.50,51  
Despite the previous trend of using more and more 
complicated modalities, some recent reports concentrate 
on simple techniques to identify the characteristic 
movement of the interventricular septum, associated with 
left bundle branch block. Such an early inward motion, 
called the “septal flash”(SF) proved  by Duckett et al to be 
associated with a specific left ventricular (LV) activation 
pattern predicting a favorable response to CRT, whether it 
was identified visually or by m-mode.52 Szulik et al, in 
order to quantify a similar phenomenon, known as the 
“apical rocking”, used an index called “apical transverse 
motion” from apical 4-chamber view and found it to be 
superior to conventional dyssynchrony indices. It is 
interesting that even the visual identification of apical 
rocking by experienced echocardiographers had high 
accuracy in predicting CRT response.53 
 
PROSPECT and Other Negative Trials  
 
Most of the encouraging data so far derive from small 
single center trials, where experienced echocardiographers 
measure a single index, in which they have particular 
expertise. However, data from multicenter trials (with the 




One of the most important reports, concerning the 
usefulness of echo indices in CRT candidate selection was 
the multi-center non-randomized PROSPECT trial, which 
examined 12 echo indices, based on M-mode, pulse wave 
Doppler and TDI. Patient population fulfilled the 
established by the guidelines (at the time of the study trial) 
criteria, with a QRS cut-off value of 130 ms, although, in 
some centers, patients with <130 ms were enrolled, if there 
were signs of mechanical dyssynchrony. Clinical response 
was defined by a composite score and echocardiographic 
response was defined by a reduction in LV end-systolic 
volume >15%. The ability of the 12 echocardiographic 
parameters to predict either clinical or echo response was 
poor; sensitivity ranged from 9% to 77% and specificity 
from 31% to 93%. All of the parameters tested had an area 
under the receiver-operating characteristics curve of 
<0.62. In addition, there appeared to be a great 
interobserver and intraoperator variability in analysis of 
dyssynchrony parameters, with coefficient of variation 
varying from 32% to 72% and from 16% to 24%, 
respectively.54  
Several aspects of this trial have been heavily criticized. 
Results may just reflect the general difficulty of the TDI 
methodology. High interobserver variability for the 
measurement of end-systolic volume raises concerns about 
the quality of echocardiography in these centers. In 
addition, 20.2% of the subjects had a core laboratory 
measured LVEF >35% and should not, therefore, have 
been included in the study. Moreover, one-third of the 
images could not be analyzed even for LV end-systolic 
volume, due to suboptimal quality. There was also a 
problem with multiple echocardiographic machines from 
different vendors, while 40% were old machines incapable 
of acquiring good quality TDI images. Criticism has also 
been made about the site selection (according to volume of 
implantation and not according to echo expertise), the 
source of funding (device manufacturer) and the minimal 
training of 1 day, which clearly would be inadequate for 
TDI analysis. Despite the serious limitations of the 
PROSPECT trial, it should be noted that study design does 
not differ significantly from real life, which still warrants 
caution in echo indices implementation.55  
On the other hand, the issue of implementing CRT in 
HF patients with narrow QRS, and echo criteria of 
dyssynchrony has been resolved. After the negative results 
of the RethinQ Study, which used M-mode techniques for 
patient selection,56 it was suggested that newer indices may 
better detect CRT responders, even with narrow QRS. 
However, two recent trials, LESSER EARTH and Echo-
CRT, found that BIV pacing in this population not only did 
not confer any clinical or echocardiographic benefit, but 
could also prove harmful.57,58  
 
Pacing Site Selection 
 
Despite the above results, which have caused 
skepticism over the adoption of echo criteria in CRT 
candidate selection, the field of CRT might still have room 
for echocardiography. It has been suggested that placement 
of the LV lead to the latest sites of contraction and away 
from the scar confers the best response to CRT. TARGET 
study tested this hypothesis, where unguided CRT 
implantation was compared to LV lead placement in the 
latest site of activation according to radial strain by STE. 
Sites with <10% amplitude in strain were dismissed due to 
possible scar presence. Patients with guided implantation 
were more frequently responders, both in echo (70% vs 
55%) and clinical parameters (83% vs 65%).59 STARTER 
trial tested the impact of similar strategy in survival rate 
free from appropriate defibrillation therapy for ventricular 
arrhythmias. Compared with the routine group, patients in 
the echo-guided group had improved CRT-D therapy-free 
survival rate (hazard ratio = 0.64) and were more likely to 
resynchronize their LV compared with the routine group 
(72% vs 48%).60 It should be kept in mind that different 
echo modalities produce varying results. Faletra et al, in 
study comparing TDI, STE, 2D and 3D echo, reported that 
agreement among indices for the presence of 
dyssynchrony was generally low (kappa -0.02). Equally 
low was the agreement of each of these echocardiographic 
indexes in determining, in the same patient with heart 




Perhaps, the most widely accepted use of 
echocardiography is the optimization of pacing settings in 
order to achieve the greatest hemodynamic benefit. In 
CLEAR trial, systematic CRT optimization was associated 
with reduced mortality and fewer hospitalizations.61 
However, optimization is not frequently performed, even 
in high-volume centers, with the exception of non-
responders, mainly due to the fact that it is laborious, time-
consuming, non-reproducible, and requires experienced 
personnel and patient cooperation.62  
Several methods for atrioventricular (AV) optimization 
have been described that include pulsed-wave Doppler 
(PWD) measurements of mitral inflow velocities, 
continuous wave Doppler of the mitral regurgitant jet 
velocity envelope, or the systolic velocity time integral 
(VTI) by pulsed-wave Doppler in the LV outflow tract or 
continuous wave Doppler (CWD) recordings of peak 
aortic flow velocities.63 Four of these methods, VTI of 
mitral inflow, VTI of LV outflow tract (LVOT), maximal 
EA duration and the Ritter formula, were compared with 
invasive hemodynamics in a previous trial. Maximal EA 
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duration (which is more frequently used in real-life 
situations) is the longest diastolic filling time until the 
abbreviation of the A wave by mitral valve closure, while 
the Ritter formula measures the time from the ventricular 
paced deflection to closure of the mitral valve at a long 
AVD interval (i.e., 160–200 ms) and at a short AVD 
interval (i.e., 50–60 ms) and the onset of electrical 
activation until the end of the A wave (QA) and is provided 
by the following equation: AV optimal=+AV short + ([AV 
long +QA long] - [AV short +QA short]. The best 
correlation with invasive hemodynamics was 
demonstrated by transmitral flow VTI, followed by 
maximal EA duration and LVOT VTI. Ritter formula 
failed to show any correlation, possibly due to the fact that 
it was devised for patients with AV block, and may not be 
applicable to HF patients.64  
Optimization of interventricular (VV) delay is less well 
established as it appears to marginally improve 
hemodynamics with no additional clinical benefit 
shown.65–69 In a study by Boriani et al, the optimization of 
the V-V delay conferred no additional benefit compared 
with simultaneous biventricular stimulation.70 In a more 
recent trial, compared with the best of the currently 
available device nominal AV and VV delays, 23-45% of 
CRT patients can yield additional acute hemodynamic 
effect by individual optimization of the delays, while a new 
nominal VV delay of 40 ms LV pre-activation was 
recommended.71 In any case, VV optimization is 
performed by achieving the maximal LVOT VTI, 
measured from the apical 5 chamber view.70   
However, the echo approach to optimizing the AV and 
VV intervals has recently been rivaled by the development 
of automated algorithms by the device manufacturers and 
the automatic programming of these intervals appears to be 
a close approximation of the more elaborate and tedious 




The role of echocardiography in patient selection for 
CRT has yet to be defined. Recent data have conclusively 
demonstrated that BiV pacing in patients with narrow 
QRS, based on echocardiographic indices, is unarguably 
contraindicated. Nevertheless, the issue of minimizing 
CRT non-responders, among those with wide QRS, is still 
open. Furthermore, the role of echocardiography for CRT 
optimization is rivaled by automated algorithms 
incorporated into the CRT devices, however, 
echocardiography might still prove important for guiding 
LV lead placement. 
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